Article
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Blood - 20 Oct 2022
Sperling Adam S, Guerra Veronica A, Kennedy James A, Yan Yuanqing, Hsu Joanne I, Wang Feng, Nguyen Andrew T, Miller Peter G, McConkey Marie E, Quevedo Barrios Vanessa A, Furudate Ken, Zhang Linda, Kanagal-Shamanna Rashmi, Zhang Jianhua, Little Latasha, Gumbs Curtis, Daver Naval, DiNardo Courtney D, Kadia Tapan, Ravandi Farhad, Kantarjian Hagop, Garcia-Manero Guillermo, Futreal P Andrew, Ebert Benjamin L, Takahashi Koichi
Abstract excerpt
There is a growing body of evidence that therapy-related myeloid neoplasms (t-MNs) with driver gene mutations arise in the background of clonal hematopoiesis (CH) under the positive selective pressure of chemo- and radiation therapies. Uncovering the exposure relationships that provide selective advantage to specific CH mutations is critical to understanding the pathogenesis and etiology of t-MNs. In a systematic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.